Skip to main content
Log in

A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Fifteen patients with recurrent squamous cell head and neck cancer were treated with deoxyspergualin. There were no objective responses in 14 evaluable patients. The most common toxicity was reversible hypotension, which prompted dose reduction in nine patients. Deoxyspergualin is not recommended for the treatment of squamous cell head and neck cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Urba SG, Forastiere AA: Systemic therapy of head and neck cancer: most effective agents, areas of promise. Oncol 3(4):79–88, 1989

    Google Scholar 

  2. Takeuchi T, Iinuma H, Kunimoto S, Masuda T, Ishizuka M, Takeuchi M, Hamada M, Naganawa H, Kondo S, Umezawa H: A new antitumor antibiotic spergualin: isolation and antitumor activity. J Antibiot (Tokyo), 34:1619–1621, 1981

    Google Scholar 

  3. Deoxyspergualin (NSC 356894). National Cancer Institute. Clinical Brochure, June 1990

  4. Muindi JF, Lee S-J, Baltzer L, Jakubowski A, Scher H, Sprancmania LA, Riley CH, Vander Velde D, Young C: Clinical pharmacology of deoxyspergualin in patients with advanced cancer. Cancer Res 51:3096–3101, 1991

    PubMed  Google Scholar 

  5. Havlin K, Koeller J: Personal communication.

  6. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981

    PubMed  Google Scholar 

  7. Pai LH, FitzGerald DJ, Tepper M, Schacter B, Spitalny G, Pastan I: Inhibition of antibody response to pseudomonas exotoxin and an immunotoxin containing pseudomonas exotoxin by 15-deoxyspergualin in mice. Cancer Res 50: 7750–7753, 1990

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Drs. Pfister and Motzer are recipients of an American Cancer Society Clinical Oncology Career Development Award.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pfister, D.G., Bajorin, D., Motzer, R.J. et al. A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer. Invest New Drugs 11, 53–56 (1993). https://doi.org/10.1007/BF00873911

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00873911

Key words

Navigation